Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel

Cancer Science
Takeo KosakaMototsugu Oya

Abstract

The present study aimed to evaluate the efficacy of cabazitaxel in Japanese patients affected by metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. In this retrospective study, 41 patients with mCRPC treated with cabazitaxel at Keio University Hospital were retrospectively reviewed. Cabazitaxel at a dose of 20-25 mg/m² was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). An upfront dose-reduction was required in 52.5% of patients due to their reduced general condition or advanced age. Prophylactic G-CSF was prescribed to all the patients. Grade ≥3 neutropenia and febrile neutropenia occurred in 21 patients (53.6%) and 3 patients (6.8%), respectively. Treatment was generally well tolerated, with a median of 5 cycles (range 1-17). Median PFS and OS from the start of cabazitaxel treatment were 4.4 and 15.0 months (95% CI 8.9-21.2), respectively. Waterfall plot analysis revealed that a prostate-specific antigen (PSA) decline >50% was noticed in n = 11 patients receiving cabazitaxel (26.8%). Univariate analysis revealed that poor pe...Continue Reading

References

Sep 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J ArmstrongMario Eisenberger
Apr 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·X PivotJ P Lotz
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alain C MitaAnthony W Tolcher
Feb 17, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kohei ShitaraKei Muro
Dec 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew J ArmstrongMario Eisenberger
May 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K ShitaraK Muro
Feb 4, 2014·Cancer Chemotherapy and Pharmacology·Hirofumi MukaiUNKNOWN TED 11576 investigators
Apr 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Antoine AngelerguesStéphane Oudard
Mar 27, 2015·International Journal of Clinical Oncology·Masahiro NozawaYoshiyuki Kakehi
Sep 9, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T Kosaka, M Oya
Feb 2, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexander MeiselFrank Stenner-Liewen
Apr 11, 2017·The Keio Journal of Medicine·Keitaro WatanabeMototsugu Oya
Aug 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mario EisenbergerJohann de Bono

❮ Previous
Next ❯

Citations

Nov 23, 2018·International Journal of Clinical Oncology·Hiroshi KobayashiSakae Tanaka
Dec 14, 2018·Molecular and Clinical Oncology·Takeo KosakaMototsugu Oya

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01324583

Software Mentioned

Statistical Package of the Social Sciences

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.